Nuformix Share Discussion Threads

[escapetohome] 10/3/2021 15:14

Seems to be improving since this morning.

Dare i say ‘blue finish’?

[escapetohome] 10/3/2021 09:43

Yup, along haul back.

One for gamblers only.

[volsung] 10/3/2021 08:38

Dis bad share. I know dis. Has lost me money in past so it has defo. A non non pour moi

[for fx sake] 10/3/2021 07:53

They're still reluctant to completely state that is dead, Soup.Look at the wording. It says they are disappointed that previous efforts haven't yielded results and that they have appointed a new business development bod to see if anything can be salvaged. Still trying to dangle that carrot to the eternally gullible.Ebers and Vistagen also dead ends!!What exactly was the massive potential she saw according to her last update?PS. Those recent TR-1 sells were nicely timed. That was lucky, wasn't it?

[amaretto1] 10/3/2021 07:42

I remember last year telling u to swap in to C4XD .....Now I'm advising u to swap in to MXC.My thoughts ... good luck.

[hodhasharon] 10/3/2021 07:25

The magic word we needed is in there. 'Oversubscribed'!

[soupdragon55] 10/3/2021 07:23

Amaretto, I'm not happy, let's just say that.

[soupdragon55] 10/3/2021 07:22

FX, it's all in there. Not good I'm afraid.

[for fx sake] 10/3/2021 07:16

NXP002 results show massive promise. What now? Oh, er, more money please for more NXP002 tests.Where is the deal reported in the Times over 18 months ago? Who leaked it and did they gain financially from it? Why are they still telling investors that discussions are still ongoing without offering any proof?Never ending gravy train.

[for fx sake] 03/3/2021 13:57

Yes. However, one might expect that if they were still discussing an NXP002 Asia deal after 18 months of zilch (as they claim), then yesterday's RNS would make it that much more attractive and might help to remove any remaining stumbling blocks..perhaps they are even approaching the point where they can finally tell us who they are actually talking too!If a deal is now more likely then I would expect some fun and games with the share price in the interim.

[escapetohome] 03/3/2021 13:40

A disappointing share price performance.

[for fx sake] 03/3/2021 13:38

There's plenty to look at. It would take some masterful incompetence IMHO to not be able to deliver on any of it.

[rp independent traders gb] 03/3/2021 13:04

Thanks, il do some more digging too.

[for fx sake] 03/3/2021 08:24

See post 7304

[rp independent traders gb] 03/3/2021 07:55

Sorry but anyone know if partnership with Ebers Tech is still ongoing after Dr Dan Gooding has resigned? Cant find any notification to market of termination of this route or further developments. Thanks

[jas964] 02/3/2021 16:29

I read that as positive news but such is the market apathy/faith(lack of) in NFX that the share price still needs checked for a pulse.

[for fx sake] 02/3/2021 09:00

Let's hope that this does draw a large partner out of the shadows and that it's not just a requirement to secure the Innovate funding. If it is only that then we are still at risk of NFX feeling encouraged enough to believe that they can take it forward themselves via a massive fundraising.

[for fx sake] 02/3/2021 08:22

Very good news. I was a bit wary at first when I saw:"..using human precision cut lung slices taken from a single IPF donor".I would have thought the results would have been better grounded if they agreed across samples from several different donors but then WTFDIK.That may be all they need to get the Innovate funding or to satisfy a partner on future collaboration.Fingers crossed

[soupdragon55] 02/3/2021 07:41

We shall see amaretto... we shall see.Anyway today is NXP002 focus, as it further backs up that NFX have something game changing.

[amaretto1] 02/3/2021 07:16

That's silently been dropped !

[soupdragon55] 02/3/2021 07:10

Big news. "The preliminary data from this study shows that the combination of NXP002 with SOC provided strong evidence of additional effects compared to either SOC alone on both fibrotic and inflammatory markers. In addition, the results showed evidence of similar or better activity of lower doses of SOC in combination with NXP002, compared to higher doses of SOC alone, indicating a potential for a dose-sparing effect of the combination. These data supplement the previously reported study of NXP002 in the same preclinical model where positive effects were seen when NXP002 was dosed alone and now there is strong data in combination with SOC therapy."

[carlisle44] 01/3/2021 16:12

I would have thought the Ebers link.(cannaboid therapeutics) would be news enough. . . . .

[stalker_boy] 01/3/2021 12:14

One day this will start to rise and not pause. Need to get a little more news flow to excite Punters